Evidence map›Paper›PMID 36519540›Full record

ArticleThe Journal of clinical investigation2022

Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.

Aonan Zhao, Yang Jiao, Guanyu Ye, Wenyan Kang, Lan Tan, Yuanyuan Li, Yulei Deng, Jun Liu, Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Aonan ZhaoDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yang JiaoDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Guanyu YeDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wenyan KangDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Lan TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong Province, China.
Yuanyuan LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yulei DengDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jun LiuDepartment of Neurology and Institute of Neurology, Ruijin Hospital affiliated with the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Ruijin Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDSoluble triggering receptor expressed on myeloid cells 2 (sTREM2) plays an important role in the clearance of pathological amyloid-β (Aβ) in Alzheimer's disease (AD). This study aimed to explore sTREM2 as a central and peripheral predictor of the conversion from mild cognitive impairment (MCI) to AD.METHODSsTREM2 and Aβ1-42 levels in cerebrospinal fluid (CSF) and florbetapir-PET (AV45) images were analyzed for healthy control (HCs), patients with MCI, and patients with AD from the ADNI database. Peripheral plasma sTREM2 and Aβ1-42 levels were determined for our Neurology database of Ruijin Hospital for Alzheimer's Disease (NRHAD) cohort, and patients with MCI were reevaluated at follow-up visits to assess for progression to AD. The association between CSF and plasma sTREM2 levels was analyzed in data from the Chinese Alzheimer's Biomarker and Lifestyle (CABLE) database.RESULTSThe results showed that patients with MCI who had low levels of CSF sTREM2 and Aβ1-42 were more likely to develop AD. Among participants with positive Aβ deposition, as assessed by AV45 imaging, elevated CSF sTREM2 levels were associated with a decreased risk of MCI-to-AD conversion. Meanwhile, in the NRHAD cohort, individuals in the MCI group with high sTREM2 levels in plasma were at a greater risk for AD, whereas low Aβ1-42 with high sTREM2 levels in plasma were associated with a faster cognitive decline. In addition, CSF sTREM2 levels were highly correlated with plasma sTREM2 levels in the CABLE database.CONCLUSIONThese findings suggest that sTREM2 may be useful as a potential predictive biomarker of MCI-to-AD conversion.FUNDINGThis study was supported by grants from the National Natural Science Foundation of China (grant nos. 82001341, 82071415, 81873778, and 82201392); the Shanghai Sailing Program (grant no. 22YF1425100); and the China Postdoctoral Science Foundation funded project (grant no. 2021M702169).

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersChinaHumansMembrane GlycoproteinsReceptors, Immunologictau ProteinsAmyloid beta-PeptidesBiomarkersMembrane GlycoproteinsReceptors, Immunologictau ProteinsTREM2 protein, humanAlzheimer diseaseDiagnosticsInflammationNeurodegenerationNeuroscience

Identifiers

PMID36519540
PMCPMC9753995
OpenAlexW4311443209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.